linifanib

has antineoplastic activity

Also Known As:

1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea; A 741439; A-741439; A741439; ABT 869; ABT-869; ABT869; N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; RG 3635; RG-3635; RG3635

Networked: 53 relevant articles (8 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Albert, Daniel H: 13 articles (08/2013 - 04/2006)
2.	Carlson, Dawn M: 12 articles (11/2015 - 08/2011)
3.	Ricker, Justin L: 10 articles (11/2015 - 08/2011)
4.	Davidsen, Steven K: 8 articles (04/2012 - 04/2006)
5.	McKee, Mark D: 6 articles (11/2015 - 06/2012)
6.	McKeegan, Evelyn M: 6 articles (11/2015 - 07/2011)
7.	Qian, Jiang: 6 articles (02/2015 - 08/2011)
8.	Chen, Chien-Shing: 6 articles (07/2014 - 07/2008)
9.	Luo, Yanping: 5 articles (08/2013 - 04/2006)
10.	Pradhan, Rajendra: 5 articles (08/2012 - 10/2009)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2015 - "This signature was associated with improved survival in patients receiving linifanib monotherapy (hazard ratio [HR]=0.51 vs signature negative; p=0.002), but not in those receiving other anti-cancer treatments (p=0.716). " 06/01/2015 - "Preclinical and early-phase trials have been showing promising efficacy results However, although signals of anti-tumor activity have been proven in some malignancies, linifanib late-phase development has been facing some challenges due to limited efficacy and increased toxicities. " 04/01/2014 - "We pooled 7,351 linifanib plasma concentrations from 1,010 cancer patients enrolled in 13 clinical studies. " 04/01/2014 - "Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients." 01/01/2014 - "The purpose of this high-precision QT study was to evaluate the effects of linifanib on cardiac repolarization in patients with advanced metastatic tumors. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/01/2011 - "Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer." 08/01/2011 - "Linifanib is active in advanced non-small cell lung cancer as second- or third-line therapy. " 11/01/2015 - "Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib." 06/01/2012 - "FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model." 02/01/2016 - "Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer."
3.	Hepatocellular Carcinoma (Hepatoma) 11/01/2013 - "Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma." 01/15/2013 - "Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma." 10/07/2020 - "Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib." 10/20/2014 - "Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib." 01/15/2013 - "Single-agent linifanib was found to be clinically active in patients with advanced hepatocellular carcinoma, with an acceptable safety profile."
4.	Breast Neoplasms (Breast Cancer) 01/01/2013 - "The purpose of this study was to demonstrate the utility of (99m)Tc-3P-RGD₂ SPECT/CT (single photon emission computed tomography/computed tomography) as a molecular imaging tool for noninvasive monitoring breast tumor early response to antiangiogenesis therapy with linifanib, and to illustrate its limitations in monitoring the efficacy of anti-α(v)β₃ treatment. " 01/01/2013 - "Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy." 01/01/2018 - "We found that the multi-tyrosine kinase inhibitor linifanib could significantly inhibit miR-10b and reverse its oncogenic function in breast cancer and liver cancer both in vitro and in vivo. " 06/01/2012 - "Four patients (lung cancer, breast cancer, thymic cancer, sarcoma) have continued linifanib for ≥48 weeks (range, 48-96+ weeks). "
5.	Hypertension (High Blood Pressure) 06/01/2012 - "The most common linifanib-related AE was hypertension. " 08/01/2011 - "The most common linifanib-related grade 3 or 4 adverse event was hypertension (14%). " 01/15/2013 - "The most common linifanib-related grade 3/4 adverse events were hypertension (25%) and fatigue (14%). " 02/01/2009 - "To assess the utility of ETA receptor blockade in controlling hypertension with RTK inhibition, we evaluated the ability of atrasentan to block hypertension with ABT-869 in conscious, telemetry-instrumented rats. " 11/01/2013 - "The most common AEs related to linifanib PK were hypertension (P = 0.02 for Cmax and P = 0.01 for AUC), diarrhea (P = 0.001 for Cmax and P = 0.0012 for AUC), proteinuria (P = 0.001 for Cmax and P = 0.002 for AUC), and asthenia (P = 0.03 for AUC). "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Biomarkers (Surrogate Marker)
3.	Carboplatin (JM8)
4.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
5.	Phosphotransferases (Kinase)
6.	Tyrosine Kinase Inhibitors
7.	Glycogen Synthase Kinase 3
8.	Sirolimus (Rapamycin)
9.	Enalapril
10.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)